Cooper Jeffrey H
Insider CIK 1301173 · BMRN SVP, Chief Financial Officer · DNAI Director · KBIO Chief Financial Officer · TBRA Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| SRRA Sierra Oncology, Inc. | D To issuer deriv | 2022-07-01 | 2022-07-01 | 1,941 | — | $0 | 0 | SEC↗ |
| SRRA Sierra Oncology, Inc. | D To issuer deriv | 2022-07-01 | 2022-07-01 | 625 | — | $0 | 0 | SEC↗ |
| SRRA Sierra Oncology, Inc. | D To issuer deriv | 2022-07-01 | 2022-07-01 | 625 | — | $0 | 0 | SEC↗ |
| SRRA Sierra Oncology, Inc. | D To issuer deriv | 2022-07-01 | 2022-07-01 | 750 | — | $0 | 0 | SEC↗ |
| SRRA Sierra Oncology, Inc. | D To issuer deriv | 2022-07-01 | 2022-07-01 | 18,061 | — | $0 | 0 | SEC↗ |
| SRRA Sierra Oncology, Inc. | D To issuer deriv | 2022-07-01 | 2022-07-01 | 6,000 | — | $0 | 0 | SEC↗ |
| SRRA Sierra Oncology, Inc. | A Award deriv | 2021-06-08 | 2021-06-09 | 6,000 | — | $0 | 6,000 | SEC↗ |
| SRRA Sierra Oncology, Inc. | A Award deriv | 2020-06-09 | 2020-06-10 | 18,061 | — | $0 | 18,061 | SEC↗ |
| SRRA Sierra Oncology, Inc. | A Award deriv | 2019-06-11 | 2019-06-12 | 30,000 | — | $0 | 30,000 | SEC↗ |
| SRRA Sierra Oncology, Inc. | A Award deriv | 2018-06-12 | 2018-06-14 | 25,000 | — | $0 | 25,000 | SEC↗ |
| SRRA Sierra Oncology, Inc. | A Award deriv | 2017-06-13 | 2017-06-14 | 25,000 | — | $0 | 25,000 | SEC↗ |
| TBRA Tobira Therapeutics, Inc. | D To issuer deriv | 2016-11-01 | 2016-11-03 | 13,539 | — | $0 | 0 | SEC↗ |
| TBRA Tobira Therapeutics, Inc. | D To issuer deriv | 2016-11-01 | 2016-11-03 | 17,778 | — | $0 | 0 | SEC↗ |
| TBRA Tobira Therapeutics, Inc. | D To issuer deriv | 2016-11-01 | 2016-11-03 | 15,500 | — | $0 | 0 | SEC↗ |
| DNAI ProNAi Therapeutics Inc | A Award deriv | 2016-06-09 | 2016-06-13 | 77,670 | — | $0 | 77,670 | SEC↗ |
| TBRA Tobira Therapeutics, Inc. | A Award deriv | 2016-01-12 | 2016-01-14 | 17,778 | — | $0 | 17,778 | SEC↗ |
| TBRA Tobira Therapeutics, Inc. | A Award deriv | 2015-07-09 | 2015-07-13 | 15,500 | — | $0 | 15,500 | SEC↗ |
| TBRA Tibira Therapeutics, Inc. | A Award deriv | 2015-05-04 | 2015-05-06 | 13,539 | — | $0 | 13,539 | SEC↗ |
| KBIO KALOBIOS PHARMACEUTICALS I | A Award deriv | 2013-04-30 | 2013-05-02 | 60,000 | — | $0 | 60,000 | SEC↗ |
| BMRN BIOMARIN PHARMACEUTICAL IN | M Exercise deriv | 2012-05-14 | 2012-05-16 | 3,750 | $14.39 | $54.0K | 153,792 | SEC↗ |
| BMRN BIOMARIN PHARMACEUTICAL IN | M Exercise deriv | 2012-05-14 | 2012-05-16 | 6,500 | $21.51 | $139.8K | 157,542 | SEC↗ |
| BMRN BIOMARIN PHARMACEUTICAL IN | M Exercise deriv | 2012-05-14 | 2012-05-16 | 15,000 | $26.49 | $397.4K | 164,042 | SEC↗ |
| BMRN BIOMARIN PHARMACEUTICAL IN | M Exercise | 2012-05-14 | 2012-05-16 | 3,750 | $14.39 | $54.0K | 66,339 | SEC↗ |
| BMRN BIOMARIN PHARMACEUTICAL IN | S Sale | 2012-05-14 | 2012-05-16 | 25,250 | $38.09 | $961.8K | 41,089 | SEC↗ |
| BMRN BIOMARIN PHARMACEUTICAL IN | M Exercise | 2012-05-14 | 2012-05-16 | 15,000 | $26.49 | $397.4K | 56,089 | SEC↗ |
| BMRN BIOMARIN PHARMACEUTICAL IN | M Exercise | 2012-05-14 | 2012-05-16 | 6,500 | $21.51 | $139.8K | 62,589 | SEC↗ |
| BMRN BIOMARIN PHARMACEUTICAL IN | A Award | 2012-04-30 | 2012-05-16 | 985 | $19.35 | $19.1K | 41,089 | SEC↗ |
| BMRN BIOMARIN PHARMACEUTICAL IN | M Exercise deriv | 2012-02-24 | 2012-02-28 | 4,864 | $17.54 | $85.3K | 257,214 | SEC↗ |
| BMRN BIOMARIN PHARMACEUTICAL IN | M Exercise deriv | 2012-02-24 | 2012-02-28 | 41,964 | $17.33 | $727.2K | 215,250 | SEC↗ |
| BMRN BIOMARIN PHARMACEUTICAL IN | M Exercise deriv | 2012-02-24 | 2012-02-28 | 8,708 | $17.86 | $155.5K | 206,542 | SEC↗ |
| BMRN BIOMARIN PHARMACEUTICAL IN | M Exercise deriv | 2012-02-24 | 2012-02-28 | 25,000 | $21.51 | $537.8K | 179,042 | SEC↗ |
| BMRN BIOMARIN PHARMACEUTICAL IN | M Exercise deriv | 2012-02-24 | 2012-02-28 | 2,500 | $14.39 | $36.0K | 204,042 | SEC↗ |
| BMRN BIOMARIN PHARMACEUTICAL IN | M Exercise | 2012-02-24 | 2012-02-28 | 8,708 | $17.86 | $155.5K | 95,640 | SEC↗ |
| BMRN BIOMARIN PHARMACEUTICAL IN | M Exercise | 2012-02-24 | 2012-02-28 | 25,000 | $21.51 | $537.8K | 123,140 | SEC↗ |
| BMRN BIOMARIN PHARMACEUTICAL IN | M Exercise | 2012-02-24 | 2012-02-28 | 2,500 | $14.39 | $36.0K | 98,140 | SEC↗ |
| BMRN BIOMARIN PHARMACEUTICAL IN | S Sale | 2012-02-24 | 2012-02-28 | 83,036 | $35.07 | $2.91M | 40,104 | SEC↗ |
| BMRN BIOMARIN PHARMACEUTICAL IN | M Exercise | 2012-02-24 | 2012-02-28 | 41,964 | $17.33 | $727.2K | 86,932 | SEC↗ |
| BMRN BIOMARIN PHARMACEUTICAL IN | M Exercise | 2012-02-24 | 2012-02-28 | 4,864 | $17.54 | $85.3K | 44,968 | SEC↗ |
| BMRN BIOMARIN PHARMACEUTICAL IN | M Exercise deriv | 2012-01-03 | 2012-01-05 | 2,500 | — | $0 | 262,078 | SEC↗ |
| BMRN BIOMARIN PHARMACEUTICAL IN | S Sale | 2012-01-03 | 2012-01-05 | 2,500 | $34.75 | $86.9K | 40,104 | SEC↗ |
| BMRN BIOMARIN PHARMACEUTICAL IN | M Exercise | 2012-01-03 | 2012-01-05 | 2,500 | $14.39 | $36.0K | 42,604 | SEC↗ |